Thomas Folinsbee
Director/Board Member chez CASI PHARMACEUTICALS, INC.
Profil
Mr. Thomas Folinsbee, CFA, is an Independent Director at CASI Pharmaceuticals, Inc. and a Director-Business Development at Shanghai Alebund Pharmaceuticals Ltd.
He is on the Board of Directors at CASI Pharmaceuticals, Inc. Mr. Folinsbee was previously employed as an Independent Director by Xynomic Pharmaceuticals Holdings, Inc., an Independent Director by Bison Capital Acquisition Corp., a Director-Corporate Development by 3SBio, Inc., and an Independent Director by Summit Healthcare Acquisition Corp.
He also served on the board at Hisanaga Seisakusho Co. Ltd.
He received his undergraduate degree from McGill University.
Postes actifs de Thomas Folinsbee
| Sociétés | Poste | Début |
|---|---|---|
| CASI PHARMACEUTICALS, INC. | Director/Board Member | 21/03/2023 |
| Shanghai Alebund Pharmaceuticals Ltd. | Corporate Officer/Principal | 01/01/2019 |
Anciens postes connus de Thomas Folinsbee
| Sociétés | Poste | Fin |
|---|---|---|
Bison Capital Acquisition Corp.
 Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Director/Board Member | 01/01/2019 |
| 3SBIO INC. | Corporate Officer/Principal | 01/01/2019 |
| Hisanaga Seisakusho Co. Ltd. | Director/Board Member | 01/01/2016 |
| SUMT HEAL | Director/Board Member | - |
| XYNOMIC PHARMACEUTICALS HOLDINGS, INC. | Director/Board Member | - |
Formation de Thomas Folinsbee
| McGill University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| 3SBIO INC. | Health Technology |
| CASI PHARMACEUTICALS, INC. | Health Technology |
| Entreprise privées | 5 |
|---|---|
| Hisanaga Seisakusho Co. Ltd. | |
Bison Capital Acquisition Corp.
Bison Capital Acquisition Corp. Financial ConglomeratesFinance Bison Capital Acquisition Corp. is currently a blank check company, which primarily engages in the acquisition, and engagement in share exchange, share reconstruction and amalgamation with, contractual control arrangement with, purchasing all or substantially all of the assets of an entity. It also plans on engaging in any other similar business combination with one or more entities. The company is headquartered in Beijing, China. | Finance |
Xynomic Pharmaceuticals Holdings, Inc.
 Xynomic Pharmaceuticals Holdings, Inc. Pharmaceuticals: MajorHealth Technology Xynomic Pharmaceuticals Holdings, Inc. is a clinical stage best-in-class oncology therapeutics biopharmaceutical company. It engages in licensing, developing and commercializing oncology drug candidates in China, US, and rest of the world. Its current pipeline mainly consists of 3 drug candidates; Xynomic owns global exclusive development, manufacturing and commercialization rights to each of these. Its lead drug candidate abexinostat is in global potentially pivotal clinical trials against renal cell carcinoma and non-Hodgkin's lymphoma. The company was founded by Yinglin Mark Xu on October 7, 2016 and is headquartered in Shanghai, China. | Health Technology |
Summit Healthcare Acquisition Corp.
 Summit Healthcare Acquisition Corp. Financial ConglomeratesFinance Summit Healthcare Acquisition Corp. operates as a blank check company. It was formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses or entities. The company was founded on December 22, 2020 and is headquartered in Hong Kong. | Finance |
| Shanghai Alebund Pharmaceuticals Ltd. |
